{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:31:58Z","timestamp":1790065918769,"version":"4.0.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s40259-022-00564-4","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T11:02:58Z","timestamp":1668855778000},"page":"73-87","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase\u00ae)"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0829-8764","authenticated-orcid":false,"given":"Amandine","family":"Dernoncourt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Liabeuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Bennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Masmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Bodeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol\u00e8ne","family":"Laville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Hurtel-Lemaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Gras-Champel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Batteux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,19]]},"reference":[{"key":"564_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nrrheum.2017.95","volume":"13","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Bijlsma JWJ, Cutolo M, McInnes IB. Managing rheumatic and musculoskeletal diseases\u2014past, present and future. Nat Rev Rheumatol. 2017;13:443\u20138.","journal-title":"Nat Rev Rheumatol"},{"key":"564_CR2","doi-asserted-by":"publisher","unstructured":"Beltagy A, Aghamajidi A, Trespidi L, Ossola W, Meroni PL. Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road. Front Pharmacol [Internet]. Frontiers; 2021 [cited 2021 Jul 19];0. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fphar.2021.621247\/full","DOI":"10.3389\/fphar.2021.621247\/full"},{"key":"564_CR3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/acr.24037","volume":"72","author":"G Bandoli","year":"2020","unstructured":"Bandoli G, Singh N, Strouse J, Baer RJ, Donovan BM, Feuer SK, et al. Mediation of adverse pregnancy outcomes in autoimmune conditions by pregnancy complications: a mediation analysis of autoimmune conditions and adverse pregnancy outcomes. Arthritis Care Res. 2020;72:256\u201364.","journal-title":"Arthritis Care Res"},{"key":"564_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bpobgyn.2019.11.004","volume":"64","author":"EC Somers","year":"2020","unstructured":"Somers EC. Pregnancy and autoimmune diseases. Best Pract Res Clin Obstet Gynaecol. 2020;64:3\u201310.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"564_CR5","doi-asserted-by":"publisher","unstructured":"Masson Regnault M, Shourick J, Jendoubi F, Tauber M, Paul C. Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review. Am J Clin Dermatol [Internet]. 2022 [cited 2022 May 3]; Available from: https:\/\/doi.org\/10.1007\/s40257-022-00679-y","DOI":"10.1007\/s40257-022-00679-y"},{"key":"564_CR6","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/apt.13547","volume":"43","author":"NA Kennedy","year":"2016","unstructured":"Kennedy NA, Warner B, Johnston EL, Flanders L, Hendy P, Ding NS, et al. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis. Aliment Pharmacol Ther. 2016;43:910\u201323.","journal-title":"Aliment Pharmacol Ther"},{"key":"564_CR7","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1002\/eji.1830260718","volume":"26","author":"NE Simister","year":"1996","unstructured":"Simister NE, Story CM, Chen HL, Hunt JS. An IgG-transporting Fc receptor expressed in the syncytiotrophoblast of human placenta. Eur J Immunol. 1996;26:1527\u201331.","journal-title":"Eur J Immunol"},{"key":"564_CR8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1600-0897.1996.tb00172.x","volume":"36","author":"A Malek","year":"1996","unstructured":"Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol. 1996;36:248\u201355.","journal-title":"Am J Reprod Immunol"},{"key":"564_CR9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","volume":"77","author":"X Mariette","year":"2018","unstructured":"Mariette X, F\u00f6rger F, Abraham B, Flynn AD, Molt\u00f3 A, Flipo R-M, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77:228\u201333.","journal-title":"Ann Rheum Dis"},{"key":"564_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jri.2016.04.284","volume":"116","author":"C Porter","year":"2016","unstructured":"Porter C, Armstrong-Fisher S, Kopotsha T, Smith B, Baker T, Kevorkian L, et al. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. J Reprod Immunol. 2016;116:7\u201312.","journal-title":"J Reprod Immunol"},{"key":"564_CR11","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s40264-021-01073-z","volume":"44","author":"A Cavadino","year":"2021","unstructured":"Cavadino A, Sandberg L, \u00d6hman I, Bergvall T, Star K, Dolk H, et al. Signal detection in EUROmediCAT: identification and evaluation of medication-congenital anomaly associations and use of vigibase as a complementary source of reference. Drug Saf. 2021;44:765\u201385.","journal-title":"Drug Saf"},{"key":"564_CR12","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s40259-021-00498-3","volume":"35","author":"G Trifir\u00f2","year":"2021","unstructured":"Trifir\u00f2 G, Isgr\u00f2 V, Ingrasciotta Y, Ientile V, L\u2019Abbate L, Foti SS, et al. Large-scale postmarketing surveillance of biological drugs for immune-mediated inflammatory diseases through an italian distributed multi-database healthcare network: the VALORE project. BioDrugs. 2021;35:749\u201364.","journal-title":"BioDrugs"},{"key":"564_CR13","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","volume":"75","author":"CG Skorpen","year":"2016","unstructured":"Skorpen CG, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795\u2013810.","journal-title":"Ann Rheum Dis"},{"key":"564_CR14","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/acr.24130","volume":"72","author":"LR Sammaritano","year":"2020","unstructured":"Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Care Res. 2020;72:461\u201388.","journal-title":"Arthritis Care Res"},{"key":"564_CR15","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1053\/j.gastro.2018.12.022","volume":"156","author":"U Mahadevan","year":"2019","unstructured":"Mahadevan U, Robinson C, Bernasko N, Boland B, Chambers C, Dubinsky M, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American gastroenterological association IBD parenthood project working group. Gastroenterology. 2019;156:1508\u201324.","journal-title":"Gastroenterology"},{"key":"564_CR16","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","volume":"11","author":"U Mahadevan","year":"2013","unstructured":"Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286\u201392.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"564_CR17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/j.gastro.2016.04.002","volume":"151","author":"M Julsgaard","year":"2016","unstructured":"Julsgaard M, Christensen LA, Gibson PR, Gearry RB, Fallingborg J, Hvas CL, et al. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology. 2016;151:110\u20139.","journal-title":"Gastroenterology"},{"key":"564_CR18","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3109\/00365521.2013.812141","volume":"48","author":"M Bortlik","year":"2013","unstructured":"Bortlik M, Machkova N, Duricova D, Malickova K, Hrdlicka L, Lukas M, et al. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-\u03b1 therapy during pregnancy: three-center study. Scand J Gastroenterol. 2013;48:951\u20138.","journal-title":"Scand J Gastroenterol"},{"key":"564_CR19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/03009742.2011.626442","volume":"41","author":"KK Viktil","year":"2012","unstructured":"Viktil KK, Engeland A, Furu K. Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers. Scand J Rheumatol. 2012;41:196\u2013201.","journal-title":"Scand J Rheumatol"},{"key":"564_CR20","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/bcp.12642","volume":"80","author":"C Weber-Schoendorfer","year":"2015","unstructured":"Weber-Schoendorfer C, Oppermann M, Wacker E, Bernard N, Beghin D, et al. Pregnancy outcome after TNF-\u03b1 inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol. 2015;80:727\u201339.","journal-title":"Br J Clin Pharmacol."},{"key":"564_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.reprotox.2013.11.004","volume":"43","author":"O Diav-Citrin","year":"2014","unstructured":"Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, Ornoy A. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol Elmsford N. 2014;43:78\u201384.","journal-title":"Reprod Toxicol Elmsford N."},{"key":"564_CR22","unstructured":"PIANO: A 1000 Patient Prospective Registry of Pregnancy Outcomes in Women With IBD Exposed to Immunomodulators and Biologic Therapy [Internet]. Epistemonikos. [cited 2022 Sep 22]. Available from: https:\/\/www.epistemonikos.org\/en\/documents\/74ab54ddb26493ee5d6490b16f6a2a2b87532d24"},{"key":"564_CR23","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/ajg.2012.218","volume":"107","author":"GR Lichtenstein","year":"2012","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Price S, et al. Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREATTM registry. Am J Gastroenterol. 2012;107:1409\u201322.","journal-title":"Am J Gastroenterol"},{"key":"564_CR24","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1136\/annrheumdis-2021-221036","volume":"81","author":"N Ghalandari","year":"2022","unstructured":"Ghalandari N, Kemper E, Crijns IH, Wolbink G, Rispens T, Smeele HT, et al. Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy. Ann Rheum Dis. 2022;81:402\u20135.","journal-title":"Ann Rheum Dis"},{"key":"564_CR25","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1177\/1759720X221087650","volume":"14","author":"M Clowse","year":"2022","unstructured":"Clowse M, Fischer-Betz R, Nelson-Piercy C, Scheuerle AE, Stephan B, Dubinsky M, et al. Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol. Ther Adv Musculoskelet Dis. 2022;14:1759.","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"564_CR26","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1038\/s41395-018-0176-7","volume":"113","author":"M Luu","year":"2018","unstructured":"Luu M, Benzenine E, Doret M, Michiels C, Barkun A, Degand T, et al. Continuous anti-TNF\u03b1 use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the French national health insurance database (EVASION). Am J Gastroenterol. 2018;113:1669\u201377.","journal-title":"Am J Gastroenterol"},{"key":"564_CR27","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/ajg.2017.501","volume":"113","author":"M Chaparro","year":"2018","unstructured":"Chaparro M, Verreth A, Lobaton T, Gravito-Soares E, Julsgaard M, Savarino E, et al. Long-term safety of in utero exposure to anti-TNF\u03b1 drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY study. Am J Gastroenterol. 2018;113:396\u2013403.","journal-title":"Am J Gastroenterol"},{"key":"564_CR28","first-page":"74","volume":"5","author":"K Perrotta","year":"2021","unstructured":"Perrotta K, Kiernan E, Bandoli G, Manaster R, Chambers C. Pregnancy outcomes following maternal treatment with rituximab prior to or during pregnancy: a case series. Rheumatol Adv Pract. 2021;5:74.","journal-title":"Rheumatol Adv Pract."},{"key":"564_CR29","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s10067-012-2156-4","volume":"32","author":"M Ojeda-Uribe","year":"2013","unstructured":"Ojeda-Uribe M, Afif N, Dahan E, Sparsa L, Haby C, Sibilia J, et al. Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol. 2013;32:695\u2013700.","journal-title":"Clin Rheumatol"},{"key":"564_CR30","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M. VigiBase, the WHO Global ICSR database system: basic facts. Drug Inf J. 2008;42:409\u201319.","journal-title":"Drug Inf J"},{"key":"564_CR31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20:109\u201317.","journal-title":"Drug Saf"},{"key":"564_CR32","unstructured":"Standardised MedDRA Queries [Internet]. [cited 2022 Sep 25]. Available from: https:\/\/www.meddra.org\/standardised-meddra-queries"},{"key":"564_CR33","unstructured":"Vigibase [Internet]. Available from: https:\/\/www.who-umc.org\/vigibase\/vigibase\/"},{"key":"564_CR34","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519\u201323.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"564_CR35","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"J-L Montastruc","year":"2011","unstructured":"Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72:905\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"564_CR36","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1109\/TITB.2005.855566A","volume":"9","author":"E Roux","year":"2005","unstructured":"Roux E, Thiessard F, Fourrier A, B\u00e9gaud B, Tubert-Bitter P. Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance. IEEE Trans Inf Technol Biomed Publ IEEE Eng Med Biol Soc. 2005;9:518\u201327.","journal-title":"IEEE Trans Inf Technol Biomed Publ IEEE Eng Med Biol Soc."},{"key":"564_CR37","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1093\/humrep\/det370","volume":"29","author":"MM Gelder","year":"2014","unstructured":"Gelder MM, Jong Berg LTW, Roeleveld N. Drugs associated with teratogenic mechanisms. Part II: a literature review of the evidence on human risks. Hum Reprod Oxf Engl. 2014;29:168\u201383.","journal-title":"Hum Reprod Oxf Engl"},{"key":"564_CR38","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1136\/gutjnl-2021-325317","volume":"71","author":"F-D Odufalu","year":"2022","unstructured":"Odufalu F-D, Long M, Lin K, Mahadevan U. Exposure to corticosteroids in pregnancy is associated with adverse perinatal outcomes among infants of mothers with inflammatory bowel disease: results from the PIANO registry. Gut. 2022;71:1766\u201372.","journal-title":"Gut"},{"key":"564_CR39","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/rheumatology\/kez405","volume":"59","author":"K Palmsten","year":"2020","unstructured":"Palmsten K, Bandoli G, Vazquez-Benitez G, Xi M, Johnson DL, Xu R, et al. Oral corticosteroid use during pregnancy and risk of preterm birth. Rheumatol Oxf Engl. 2020;59:1262\u201371.","journal-title":"Rheumatol Oxf Engl."},{"key":"564_CR40","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12916-017-0845-1","volume":"15","author":"AA Veroniki","year":"2017","unstructured":"Veroniki AA, Cogo E, Rios P, Straus SE, Finkelstein Y, Kealey R, et al. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Med. 2017;15:95.","journal-title":"BMC Med"},{"key":"564_CR41","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1097\/AOG.0b013e3182a9ca67","volume":"122","author":"KE Shields","year":"2013","unstructured":"Shields KE, Lyerly AD. Exclusion of pregnant women from industry-sponsored clinical trials. Obstet Gynecol. 2013;122:1077\u201381.","journal-title":"Obstet Gynecol"},{"key":"564_CR42","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40259-020-00447-6","volume":"34","author":"P Wiland","year":"2020","unstructured":"Wiland P, Jeka S, Dokoupilov\u00e1 E, Brandt-J\u00fcrgens J, Miranda Lim\u00f3n JM, Cantalejo Moreira M, et al. Switching to biosimilar SDZ-ADL in patients with moderate-to-severe active rheumatoid arthritis: 48-week efficacy, safety and immunogenicity results from the phase III, randomized double-blind ADMYRA study. BioDrugs. 2020;34:809\u201323.","journal-title":"BioDrugs"},{"key":"564_CR43","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40259-020-00406-1","volume":"34","author":"VM Haridas","year":"2020","unstructured":"Haridas VM, Katta R, Nalawade A, Kharkar S, Zhdan V, Garmish O, et al. Pharmacokinetic similarity and comparative pharmacodynamics, safety, efficacy, and immunogenicity of DRL_RI versus reference rituximab in biologics-na\u00efve patients with moderate-to-severe rheumatoid arthritis: a double-blind, randomized, three-arm study. BioDrugs. 2020;34:183\u201396.","journal-title":"BioDrugs"},{"key":"564_CR44","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/aps.2012.51","volume":"33","author":"L Zhao","year":"2012","unstructured":"Zhao L, Ren T, Wang DD. Clinical pharmacology considerations in biologics development. Acta Pharmacol Sin. 2012;33:1339\u201347.","journal-title":"Acta Pharmacol Sin"},{"key":"564_CR45","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1016\/S0264-410X(03)00334-7","volume":"21","author":"NE Simister","year":"2003","unstructured":"Simister NE. Placental transport of immunoglobulin G. Vaccine. 2003;21:3365\u20139.","journal-title":"Vaccine"},{"key":"564_CR46","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3390\/jcm11010225","volume":"11","author":"M-E Brien","year":"2021","unstructured":"Brien M-E, Gaudreault V, Hughes K, Hayes DJL, Heazell AEP, Girard S. A systematic review of the safety of blocking the IL-1 system in human pregnancy. J Clin Med. 2021;11:225.","journal-title":"J Clin Med"},{"key":"564_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2020.101529","volume":"34","author":"S Georgin-Lavialle","year":"2020","unstructured":"Georgin-Lavialle S, Ducharme-Benard S, Sarrabay G, Savey L, Grateau G, Hentgen V. Systemic autoinflammatory diseases: Clinical state of the art. Best Pract Res Clin Rheumatol. 2020;34: 101529.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"564_CR48","unstructured":"Drug Approval Package: Arcalyst (Rilonacept) NDA #125249 [Internet]. [cited 2021 Aug 30]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/125249s000TOC.cfm"},{"key":"564_CR49","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.bone.2010.04.611","volume":"47","author":"R Pacifici","year":"2010","unstructured":"Pacifici R. T cells: critical bone regulators in health and disease. Bone. 2010;47:461\u201371.","journal-title":"Bone"},{"key":"564_CR50","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semarthrit.2015.06.016","volume":"45","author":"M Kumar","year":"2015","unstructured":"Kumar M, Ray L, Vemuri S, Simon TA. Pregnancy outcomes following exposure to abatacept during pregnancy. Semin Arthritis Rheum. 2015;45:351\u20136.","journal-title":"Semin Arthritis Rheum"},{"key":"564_CR51","first-page":"688","volume":"33","author":"C Bazzani","year":"2015","unstructured":"Bazzani C, Scrivo R, Andreoli L, Baldissera E, Biggioggero M, Canti V, et al. Prospectively-followed pregnancies in patients with inflammatory arthritis taking biological drugs: an Italian multicentre study. Clin Exp Rheumatol. 2015;33:688\u201393.","journal-title":"Clin Exp Rheumatol"},{"key":"564_CR52","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.semarthrit.2019.03.011","volume":"49","author":"S Kishore","year":"2019","unstructured":"Kishore S, Mittal V, Majithia V. Obstetric outcomes in women with rheumatoid arthritis: results from nationwide inpatient sample database 2003\u20132011\u2730. Semin Arthritis Rheum. 2019;49:236\u201340.","journal-title":"Semin Arthritis Rheum"},{"key":"564_CR53","doi-asserted-by":"publisher","unstructured":"Xie W, Huang H, Ji L, Zhang Z. Maternal and neonatal outcomes in pregnant women with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Rheumatology [Internet]. 2021 [cited 2021 Aug 23]; Available from: https:\/\/doi.org\/10.1093\/rheumatology\/keab357","DOI":"10.1093\/rheumatology\/keab357"},{"key":"564_CR54","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/ecco-jcc\/jjaa225","volume":"15","author":"M-A Kim","year":"2021","unstructured":"Kim M-A, Kim Y-H, Chun J, Lee HS, Park SJ, Cheon JH, et al. The influence of disease activity on pregnancy outcomes in women with inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2021;15:719\u201332.","journal-title":"J Crohns Colitis"},{"key":"564_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j895","volume":"356","author":"RJ Desai","year":"2017","unstructured":"Desai RJ, Bateman BT, Huybrechts KF, Patorno E, Hernandez-Diaz S, Park Y, et al. Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study. BMJ. 2017;356: j895.","journal-title":"BMJ"},{"key":"564_CR56","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.semarthrit.2021.06.005","volume":"51","author":"J-H Kao","year":"2021","unstructured":"Kao J-H, Lan T-Y, Lu C-H, Cheng C-F, Huang Y-M, Shen C-Y, et al. Pregnancy outcomes in patients treated with belimumab: report from real-world experience. Semin Arthritis Rheum. 2021;51:963\u20138.","journal-title":"Semin Arthritis Rheum"},{"key":"564_CR57","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383:1117\u201328.","journal-title":"N Engl J Med"},{"key":"564_CR58","doi-asserted-by":"publisher","first-page":"980079","DOI":"10.3389\/fimmu.2022.980079","volume":"13","author":"KA Kirou","year":"2022","unstructured":"Kirou KA, Dall\u2019Era M, Aranow C, Anders H-J. Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. Front Immunol. 2022;13:980079.","journal-title":"Front Immunol"},{"key":"564_CR59","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1136\/annrheumdis-2021-eular.2862","volume":"80","author":"F Crisafulli","year":"2021","unstructured":"Crisafulli F, Gerardi MC, Moschetti L, Fredi M, Nalli C, Urban ML, et al. Pos0702 pregnancy in sle patients treated with belimumab: experience from 3 Italian centers. Ann Rheum Dis. 2021;80:600\u20131.","journal-title":"Ann Rheum Dis"},{"key":"564_CR60","doi-asserted-by":"crossref","unstructured":"Juliao P, Wurst K, Pimenta JM, Gemzoe K, Landy H, Moody MA, et al. Belimumab use during pregnancy: Interim results of the belimumab pregnancy registry. Birth Defects Res [Internet]. [cited 2022 Oct 3];n\/a. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/bdr2.2091","DOI":"10.1002\/bdr2.2091"},{"key":"564_CR61","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40259-018-0285-2","volume":"32","author":"AGS Araujo","year":"2018","unstructured":"Araujo AGS, Borba HHL, Tonin FS, Lenzi L, Venson R, Pontarolo R, et al. Safety of biologics approved for the treatment of rheumatoid arthritis and other autoimmune diseases: a disproportionality analysis from the FDA adverse event reporting system (FAERS). BioDrugs. 2018;32:377\u201390.","journal-title":"BioDrugs"},{"key":"564_CR62","unstructured":"Technical description of vigiGradeTM Completeness score [Internet]. [cited 2022 Sep 25]. Available from: https:\/\/www.zva.gov.lv\/archive\/doc_upl\/Technical-description-of-vigiGrade-Completeness-score.pdf"},{"key":"564_CR63","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40264-013-0131-x","volume":"37","author":"T Bergvall","year":"2014","unstructured":"Bergvall T, Nor\u00e9n GN, Lindquist M. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf. 2014;37:65\u201377.","journal-title":"Drug Saf"},{"key":"564_CR64","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cnur.2018.01.010","volume":"53","author":"N Holness","year":"2018","unstructured":"Holness N. High-risk pregnancy. Nurs Clin N Am. 2018;53:241\u201351.","journal-title":"Nurs Clin N Am"},{"key":"564_CR65","unstructured":"Guideline for using VigiBase data in studies [Internet]. [cited 2022 Sep 25]. Available from: https:\/\/who-umc.org\/media\/05kldqpj\/guidelineusingvigibaseinstudies.pdf"},{"key":"564_CR66","unstructured":"Pregnancy and neonatal topics (SMQ) [Internet]. [cited 2022 Sep 25]. Available from: https:\/\/bioportal.bioontology.org\/ontologies\/MEDDRA?p=classes&conceptid=20000185"},{"key":"564_CR67","unstructured":"Guideline on the exposure to medicinal products during pregnancy: need for post-authorisation data [Internet]. [cited 2022 Sep 25]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-exposure-medicinal-products-during-pregnancy-need-post-authorisation-data_en.pdf"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00564-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-022-00564-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00564-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T11:11:51Z","timestamp":1673521911000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-022-00564-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,19]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["564"],"URL":"https:\/\/doi.org\/10.1007\/s40259-022-00564-4","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,19]]},"assertion":[{"value":"25 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AD contributed to the conception\/design of the work, acquisition, analysis, and interpretation of data for the work, and drafting the manuscript. She approved the version to be published, and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. SL contributed to the analysis and interpretation of data for the work, and drafting the manuscript. She approved the version to be published, and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. YB revised the work critically for important intellectual content. He approved the version to be published, and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. KM revised the work critically for important intellectual content. He approved the version to be published, and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. SB revised the work critically for important intellectual content. She approved the version to be published, and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. SL revised the work critically for important intellectual content. She approved the version to be published, and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. ASHL revised the work critically for important intellectual content. She approved the version to be published, and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. VGC contributed to the analysis and interpretation of data for the work, and drafting the manuscript. She approved the version to be published, and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. BB contributed to the conception\/design of the work, acquisition, analysis, and interpretation of data for the work, and drafting the manuscript. He approved the version to be published, and agrees to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This research did not receive any specific funding from agencies in the public, commercial, or not-for-profit sectors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent to participate\/publish"}},{"value":"The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}